2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Chugai Pharma USA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis GM-611 - Gastroparesis | Phase 2 | Completed | Chugai Pharma USA | 2005-06-24 | ||
| A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. BO-653 - Graft Occlusion, Vascular, Coronary Restenosis | Phase 2 / Phase 3 | Completed | Chugai Pharma USA | 2005-06-24 |
Atherosclerosis (1) · Coronary Restenosis (1) · Gastroparesis (1) · Graft Occlusion, Vascular (1)
2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran (1) · mitemcinal (1)
United States (2)